Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24847832 | 0.98 | MAPKAPK2 (0.54) | MAPKAPK2CDC7 | |
| SCHEMBL26443735 | 0.96 | MAPKAPK2 (0.56) | MAPKAPK2CDC7 | |
| SCHEMBL26449268 | 0.89 | MAPKAPK2 (0.50) | MAPKAPK2CDC7 | |
| SCHEMBL24846729 | 0.88 | MAPKAPK2 (0.51) | MAPKAPK2CDC7 | |
| SCHEMBL26449295 | 0.87 | MAPKAPK2 (0.52) | MAPKAPK2CDC7 | |
| SCHEMBL24847381 | 0.86 | MAPKAPK2 (0.53) | MAPKAPK2CDC7 | |
| SCHEMBL24847430 | 0.86 | MAPKAPK2 (0.69) | MAPKAPK2 | |
| SCHEMBL24847509 | 0.86 | MAPKAPK2 (0.53) | MAPKAPK2CDC7 | |
| SCHEMBL29306726 | 0.85 | MAPKAPK2 (0.53) | MAPKAPK2CDC7 | |
| SCHEMBL26443765 | 0.84 | MAPKAPK2 (0.50) | MAPKAPK2CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148060-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | MAPKAPK2 70/4885CDC7 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.